-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Using antibody-drug conjugates (ADC) to target CD79B is an effective treatment strategy for B-cell non-Hodgkin's lymphoma (B-NHL)
Using antibody-drug conjugates (ADC) to target CD79B is an effective treatment strategy for B-cell non-Hodgkin's lymphoma (B-NHL)
This is a phase 1 clinical trial that recruited 60 histologically confirmed patients with B-cell non-Hodgkin's lymphoma who had relapsed after previous (≥1 line) treatment or had failed treatment: 41 (68%) Diffuse large B-cell lymphoma (DLBCL)
Research design
Research designThe results of the study showed that 54 (90%) patients experienced side effects related to the study drug , the most common of which were blurred vision, fatigue, corneal deposition, neutropenia, nausea, and peripheral neuropathy
54 (90%) patients experienced side effects related to the study drug
Treatment response
Treatment responseThe remission rate of all patients (n=60) receiving treatment was 47% (n=28), including 17 cases of complete remission (28%) and 11 cases of partial remission
The remission rate of all patients (n=60) receiving treatment was 47% (n=28), including 17 cases of complete remission (28%) and 11 cases of partial remission
The anti-CD79B antibody drug conjugate DCDS0780A can induce deep remission in patients with B-cell non-Hodgkin's lymphoma
Original source:
Original source:Alex F.
Leave a message here
